Drugs / DC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02632201 Background | Sep 2015 → Mar 2017 | gastric cancer | Second Military Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02632201 ↗ |
| Modality | Cell therapy | “DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin)” NCT02632201 ↗ |
| Route | Subcutaneous | “DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion” NCT02632201 ↗ |